242 related articles for article (PubMed ID: 35131658)
1. Antiviral effects of azithromycin: A narrative review.
Khoshnood S; Shirani M; Dalir A; Moradi M; Haddadi MH; Sadeghifard N; Birjandi FS; Yashmi I; Heidary M
Biomed Pharmacother; 2022 Mar; 147():112682. PubMed ID: 35131658
[TBL] [Abstract][Full Text] [Related]
2. Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection.
Khezri MR; Zolbanin NM; Ghasemnejad-Berenji M; Jafari R
Eur J Pharmacol; 2021 Aug; 905():174191. PubMed ID: 34015317
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
4. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
5. Azithromycin in viral infections.
Oliver ME; Hinks TSC
Rev Med Virol; 2021 Mar; 31(2):e2163. PubMed ID: 32969125
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840
[TBL] [Abstract][Full Text] [Related]
7. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
Hache G; Rolain JM; Gautret P; Deharo JC; Brouqui P; Raoult D; Honoré S
Microb Drug Resist; 2021 Mar; 27(3):281-290. PubMed ID: 33729874
[TBL] [Abstract][Full Text] [Related]
8. Azithromycin in the treatment of COVID-19: a review.
Echeverría-Esnal D; Martin-Ontiyuelo C; Navarrete-Rouco ME; De-Antonio Cuscó M; Ferrández O; Horcajada JP; Grau S
Expert Rev Anti Infect Ther; 2021 Feb; 19(2):147-163. PubMed ID: 32853038
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance.
Rodrigues C; Freitas-Santos RS; Levi JE; Senerchia AA; Lopes ATA; Santos SR; Siciliano RF; Pierrotti LC
Int J Antimicrob Agents; 2021 Nov; 58(5):106428. PubMed ID: 34454044
[TBL] [Abstract][Full Text] [Related]
10. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.
Elshabrawy HA; Fan J; Haddad CS; Ratia K; Broder CC; Caffrey M; Prabhakar BS
J Virol; 2014 Apr; 88(8):4353-65. PubMed ID: 24501399
[TBL] [Abstract][Full Text] [Related]
11. Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin.
Du X; Zuo X; Meng F; Han C; Ouyang W; Han Y; Gu Y; Zhao X; Xu F; Qin FX
Cell Prolif; 2021 Jan; 54(1):e12953. PubMed ID: 33211371
[TBL] [Abstract][Full Text] [Related]
12. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model.
Cochin M; Touret F; Driouich JS; Moureau G; Petit PR; Laprie C; Solas C; de Lamballerie X; Nougairède A
Antiviral Res; 2022 Jan; 197():105212. PubMed ID: 34838583
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
Sargiacomo C; Sotgia F; Lisanti MP
Aging (Albany NY); 2020 Mar; 12(8):6511-6517. PubMed ID: 32229706
[TBL] [Abstract][Full Text] [Related]
15. Azithromycin Use in COVID-19 Patients: Implications on the Antimicrobial Resistance.
Seabra G; Ventura Mendes RF; Dos Santos Amorim LFV; Peregrino IV; Branquinha MH; Dos Santos ALS; Nunes APF
Curr Top Med Chem; 2021; 21(8):677-683. PubMed ID: 34028347
[No Abstract] [Full Text] [Related]
16. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
17. A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?
Vitiello A; Ferrara F
Immunol Res; 2022 Feb; 70(1):129-133. PubMed ID: 34739696
[TBL] [Abstract][Full Text] [Related]
18. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.
Maisonnasse P; Guedj J; Contreras V; Behillil S; Solas C; Marlin R; Naninck T; Pizzorno A; Lemaitre J; Gonçalves A; Kahlaoui N; Terrier O; Fang RHT; Enouf V; Dereuddre-Bosquet N; Brisebarre A; Touret F; Chapon C; Hoen B; Lina B; Calatrava MR; van der Werf S; de Lamballerie X; Le Grand R
Nature; 2020 Sep; 585(7826):584-587. PubMed ID: 32698191
[TBL] [Abstract][Full Text] [Related]
19. Virucidal Activity of World Health Organization-Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses.
Siddharta A; Pfaender S; Vielle NJ; Dijkman R; Friesland M; Becker B; Yang J; Engelmann M; Todt D; Windisch MP; Brill FH; Steinmann J; Steinmann J; Becker S; Alves MP; Pietschmann T; Eickmann M; Thiel V; Steinmann E
J Infect Dis; 2017 Mar; 215(6):902-906. PubMed ID: 28453839
[TBL] [Abstract][Full Text] [Related]
20. Effect of the Phytochemical Agents against the SARS-CoV and Some of them Selected for Application to COVID-19: A Mini-Review.
Idrees M; Khan S; Memon NH; Zhang Z
Curr Pharm Biotechnol; 2021; 22(4):444-450. PubMed ID: 32619167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
